BONESUPPORT raised SEK 327MM (~US $37MM) in equity and debt finance. Funds will support clinical data collection, product pipeline development and expansion of CERAMENT injectable osteoconductive bioceramic product sales in existing and new markets.
Specifically, the funds will be used to:
- Drive sales of CERAMENT BVF, CERAMENT G and CERAMENT V in existing and new markets.
- Generate further clinical data to highlight the compelling benefits of current CERAMENT products and to conduct the FORTIFY study to support a planned PMA filing in the U.S. for CERAMENT G.
Sources: BONESUPPORT AB; ORTHOWORLD Inc.
BONESUPPORT raised SEK 327MM (~US $37MM) in equity and debt finance. Funds will support clinical data collection, product pipeline development and expansion of CERAMENT injectable osteoconductive bioceramic product sales in existing and new markets.
Specifically, the funds will be used to:
Drive sales of CERAMENT BVF, CERAMENT G and...
BONESUPPORT raised SEK 327MM (~US $37MM) in equity and debt finance. Funds will support clinical data collection, product pipeline development and expansion of CERAMENT injectable osteoconductive bioceramic product sales in existing and new markets.
Specifically, the funds will be used to:
- Drive sales of CERAMENT BVF, CERAMENT G and CERAMENT V in existing and new markets.
- Generate further clinical data to highlight the compelling benefits of current CERAMENT products and to conduct the FORTIFY study to support a planned PMA filing in the U.S. for CERAMENT G.
Sources: BONESUPPORT AB; ORTHOWORLD Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.